Relation between TP53 GOF mutation and Osimertinib treatment in EGFR mutant lung cancer: ChIP-seq
Ontology highlight
ABSTRACT: Background: Although TP53 gain-of-function (GOF) mutations promote cancer survival, its effect on EGFR-TKI efficacy remains unclear. We established EGFR-mutant lung cancer cell lines expressing various TP53 genotypes using CRISPR-Cas9 technology and found that TP53-GOF mutant cells develop an early resistance to EGFR-TKI osimertinib.The goal of this study is to elucidate the mechanisms underlying resistance to osimertinib treatment in TP53 GOF mutations through comprehensive gene analysis using ChIP-seq.
ORGANISM(S): Homo sapiens
PROVIDER: GSE253478 | GEO | 2024/01/22
REPOSITORIES: GEO
ACCESS DATA